WEBULL
WebtradeDownload

TG Therapeutics (TGTX) Stock May Be Undervalued On Its Earnings Story

Simply Wall St · 2d ago

TG Therapeutics has turned into a major talking point after a very strong multi year share price run, and the obvious question now is whether that move still lines up with what its earnings can support. With the stock most recently closing at US$56.47, investors are starting to ask if the current valuation is being carried by fundamentals or mainly by past momentum.

  • Over the past 3 years the share price has delivered a very large gain, which puts real pressure on the earnings profile to justify where the market now values the business.
  • The company’s story now leans heavily on how efficiently it can convert its commercial portfolio and pipeline into consistent profits, since earnings quality and predictability often drive how much investors are willing to pay for each dollar of income.
  • Your read on TG Therapeutics is one view; the desks covering it have another. See what analysts think TG Therapeutics's shares could be worth.

The issue now is whether TG Therapeutics' current share price fairly reflects the earnings it is producing today.

If you are considering whether TG Therapeutics' share price is fully supported by its earnings profile, you might want to apply the same valuation approach to 29 high quality undervalued stocks.

Is TG Therapeutics Still Cheap on Earnings?

The P/E ratio is a useful lens for TG Therapeutics because investors are weighing what they pay today against the earnings stream already visible. At around 18.1x earnings, the stock trades very close to the broader Biotechs industry average of about 17.1x, so on raw sector comparison it does not screen as extreme in either direction.

What changes the picture is how that figure compares with a more tailored benchmark that adjusts for TG Therapeutics' own growth assumptions, profitability profile, size and risk. On that measure the current 18.1x P/E sits below the level that model would suggest for the business. This implies the market is pricing the shares at a discount to those company specific characteristics rather than at a premium. Explore the numbers behind TG Therapeutics's P/E valuation.

NasdaqCM:TGTX P/E Ratio as at Sep 2026
NasdaqCM:TGTX P/E Ratio as at Sep 2026

The TG Therapeutics Narrative: What Would Justify Today's Price?

TG Therapeutics' Simply Wall St Narratives pick up where the P/E puzzle leaves off and explain what kind of growth path, margin shape and earnings profile would need to occur for the stock to appear meaningfully mispriced in either direction. Each narrative links its number to a concrete view of where growth, profitability and risk could move next. This gives you a reference point to revisit as new information on TG Therapeutics' business arrives on the Community page.

Community views on TG Therapeutics now split between a meaningful upside scenario and a sharply more cautious take on how much is already priced in.

Bull case: 19% undervalued

"The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35 to 40% of the anti-CD20 MS market segment…"

Discover why this Narrative puts TG Therapeutics at 19% undervalued.

Bear case: 96% overvalued

"The heavy reliance on BRIUMVI for revenue, combined with a narrow commercial portfolio and slow pipeline progression, leaves TG Therapeutics extremely exposed to competitive threats…"

Explore why this Narrative puts TG Therapeutics at 96% overvalued.

The open question for TG Therapeutics, what are expectations a few years from now really baking in?

Short term pricing only tells part of the story, because analyst projections offer a separate lens on where this business might be heading and how that stacks up against today’s multiple. Explore where analysts expect TG Therapeutics to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.